Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy in other blood and solid cancers, these therapies have yielded limited success in clinical trials for both newly diagnosed and recurrent GBM. A deeper understanding of GBM’s resistance to immunotherapy is essential for enhancing treatment responses and translating results seen in other cancer models. Objectives: In this review, we examine clinical trial outcomes involving ICIs and CAR-T for GBM patients and explore the evasive mechanisms of GBM and the tumor microenvironment. Findings and Discussion: Multiple clinical trials investigating ICIs in GBM have shown poor outcomes, with no significant improvement in progression-free survival (PFS) or overall survival (OS). Results from smaller case studies with CAR-T therapy have warranted further investigation. However, no large-scale trials or robust studies have yet established these immunotherapeutic approaches as definitive treatment strategies. Future research should shift focus from addressing the scarcity of functional T cells to exploiting the abundant myeloid-derived cells within the tumor microenvironment. Conclusions: Translating these therapies into effective treatments for glioblastoma in humans remains a significant challenge. The highly immunosuppressive nature of GBM and its tumor microenvironment continue to hinder the success of these innovative immunotherapeutic approaches. Targeting the myeloid-derived compartment may lead to more robust and sustained immune responses.
Background/Objectives: Noninvasive brain stimulation (NIBS) can boost motor recovery after a stroke. Certain movement phases are more responsive to NIBS, so a system that auto-detects these phases would optimize stimulation timing. This study assessed the effectiveness of various machine learning models in identifying movement phases in hemiparetic individuals undergoing simultaneous NIBS and EEG recordings. We hypothesized that transcranial direct current stimulation (tDCS), a form of NIBS, would enhance EEG signals related to movement phases and improve classification accuracy compared to sham stimulation. Methods: EEG data from 10 chronic stroke patients and 11 healthy controls were recorded before, during, and after tDCS. Eight machine learning algorithms and five ensemble methods were used to classify two movement phases (hold posture and reaching) during each of these periods. Data preprocessing included z-score normalization and frequency band power binning. Results: In chronic stroke participants who received active tDCS, the classification accuracy for hold vs. reach phases increased from pre-stimulation to the late intra-stimulation period (72.2% to 75.2%, p < 0.0001). Late active tDCS surpassed late sham tDCS classification (75.2% vs. 71.5%, p < 0.0001). Linear discriminant analysis was the most accurate (74.6%) algorithm with the shortest training time (0.9 s). Among ensemble methods, low gamma frequency (30–50 Hz) achieved the highest accuracy (74.5%), although this result did not achieve statistical significance for actively stimulated chronic stroke participants. Conclusions: Machine learning algorithms showed enhanced movement phase classification during active tDCS in chronic stroke participants. These results suggest their feasibility for real-time movement detection in neurorehabilitation, including brain–computer interfaces for stroke recovery.